دورية أكاديمية
أعرض في EDS

Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade.

التفاصيل البيبلوغرافية
العنوان: Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade.
المؤلفون: Ree AH; Department of Oncology, Akershus University Hospital, Lørenskog, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Høye E; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Tumor Biology, Oslo University Hospital, Oslo, Norway., Esbensen Y; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Clinical Molecular Biology, Akershus University Hospital, Lørenskog, Norway., Beitnes AR; Department of Pathology, Akershus University Hospital, Lørenskog, Norway., Negård A; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Radiology, Akershus University Hospital, Lørenskog, Norway., Bernklev L; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway., Tetlie LK; Department of Oncology, Sørlandet Hospital, Kristiansand, Norway., Fretland ÅA; The Intervention Centre and Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Oslo, Norway., Hamre HM; Department of Oncology, Akershus University Hospital, Lørenskog, Norway., Kersten C; Department of Oncology, Akershus University Hospital, Lørenskog, Norway.; Department of Research, Sørlandet Hospital, Kristiansand, Norway., Hofsli E; Department of Oncology, St. Olav's Hospital, Trondheim, Norway.; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Guren MG; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Oncology, Oslo University Hospital, Oslo, Norway., Sorbye H; Department of Oncology, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway., Nilsen HL; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Clinical Molecular Biology, Akershus University Hospital, Lørenskog, Norway.; Department of Microbiology, Oslo University Hospital, Oslo, Norway., Flatmark K; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Tumor Biology, Oslo University Hospital, Oslo, Norway.; Department of Gastroenterological Surgery, Oslo University Hospital, Oslo, Norway., Meltzer S; Department of Oncology, Akershus University Hospital, Lørenskog, Norway.
المصدر: Oncoimmunology [Oncoimmunology] 2024 Jun 28; Vol. 13 (1), pp. 2372886. Date of Electronic Publication: 2024 Jun 28 (Print Publication: 2024).
نوع المنشور: Journal Article; Case Reports; Randomized Controlled Trial
اللغة: English
بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Internet ISSN: 2162-402X (Electronic) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: MEDLINE
أسماء مطبوعة: Publication: 2015- : Philadelphia, PA : Taylor & Francis
Original Publication: Austin, TX : Landes Bioscience
مواضيع طبية MeSH: Oxaliplatin*/therapeutic use , Oxaliplatin*/administration & dosage , Proto-Oncogene Proteins B-raf*/genetics , Proto-Oncogene Proteins B-raf*/antagonists & inhibitors , Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/genetics , Colorectal Neoplasms*/pathology , Immune Checkpoint Inhibitors*/therapeutic use , Immune Checkpoint Inhibitors*/pharmacology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Female ; Aged ; Mutation ; Microsatellite Instability/drug effects ; Treatment Outcome ; Aged, 80 and over
مستخلص: The randomized METIMMOX trial (NCT03388190) examined if patients with previously untreated, unresectable abdominal metastases from microsatellite-stable (MSS) colorectal cancer (CRC) might benefit from potentially immunogenic, short-course oxaliplatin-based chemotherapy alternating with immune checkpoint blockade (ICB). Three of 38 patients assigned to this experimental treatment had metastases from BRAF -mutant MSS-CRC, in general a poor-prognostic subgroup explored here. The ≥70-year-old females presented with ascending colon adenocarcinomas with intermediate tumor mutational burden (6.2-11.8 mutations per megabase). All experienced early disappearance of the primary tumor followed by complete response of all overt metastatic disease, resulting in progression-free survival as long as 20-35 months. However, they encountered recurrence at previously unaffected sites and ultimately sanctuary organs, or as intrahepatic tumor evolution reflected in the terminal loss of initially induced T-cell clonality in liver metastases. Yet, the remarkable first-line responses to short-course oxaliplatin-based chemotherapy alternating with ICB may offer a novel therapeutic option to a particularly hard-to-treat MSS-CRC subgroup.
Competing Interests: AHR has received research support from Bristol-Myers Squibb (on behalf of Akershus University Hospital) and served on advisory board of Takeda. HMH has received personal honoraria from Bayer and Roche and served on advisory boards of AstraZeneca, Eisai, and InCyte. CK has served on advisory boards of AstraZeneca and Roche. HS has received personal honoraria from Ipsen, Pierre Fabre, Daiichi Sankyo, and SAM Nordic and served on advisory board of AAA Pharma. SM has served on advisory board of GSK. The other authors report there are no competing interests to declare.
(© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.)
References: Nat Med. 2015 Nov;21(11):1350-6. (PMID: 26457759)
N Engl J Med. 2020 Dec 3;383(23):2207-2218. (PMID: 33264544)
JCO Precis Oncol. 2023 Sep;7:e2200694. (PMID: 37656949)
Proc Natl Acad Sci U S A. 2021 Nov 9;118(45):. (PMID: 34725151)
Crit Rev Oncol Hematol. 2017 May;113:242-248. (PMID: 28427513)
Cancer Res Commun. 2023 Oct 12;3(10):2082-2095. (PMID: 37768208)
Ann Oncol. 2023 Jun;34(6):543-552. (PMID: 36921693)
Br J Cancer. 2024 Jan;130(1):143-150. (PMID: 38040818)
J Clin Oncol. 2022 Jan 10;40(2):161-170. (PMID: 34637336)
Cancer Biol Ther. 2020 May 3;21(5):432-440. (PMID: 32098573)
J Clin Oncol. 2020 Aug 20;:JCO2001225. (PMID: 32816630)
Expert Rev Anticancer Ther. 2023 Jul-Dec;23(8):797-806. (PMID: 37482749)
Clin Colorectal Cancer. 2024 Feb 16;:. (PMID: 38519391)
Oncologist. 2024 May 3;29(5):e580-e600. (PMID: 38309719)
Eur J Cancer. 2024 Jan;196:113437. (PMID: 37980853)
N Engl J Med. 2019 Oct 24;381(17):1632-1643. (PMID: 31566309)
Front Oncol. 2023 May 05;13:1166545. (PMID: 37213293)
Cancer Med. 2019 Jul;8(7):3623-3635. (PMID: 31070306)
J Natl Cancer Inst. 2021 Oct 1;113(10):1386-1395. (PMID: 33734401)
Nat Med. 2021 Jan;27(1):152-164. (PMID: 33398162)
N Engl J Med. 2021 Mar 25;384(12):1168-1170. (PMID: 33761214)
Gigascience. 2022 Dec 28;12:. (PMID: 37161965)
J Clin Oncol. 2023 May 10;41(14):2628-2637. (PMID: 36763936)
Expert Opin Biol Ther. 2023 Jul-Dec;23(7):595-601. (PMID: 37318031)
Genome Med. 2015 May 28;7(1):49. (PMID: 26140055)
JAMA Netw Open. 2021 Aug 2;4(8):e2118416. (PMID: 34369992)
Br J Cancer. 2024 Jun;130(12):1921-1928. (PMID: 38664577)
فهرسة مساهمة: Keywords: BRAF mutation; T-cell receptor; colorectal cancer; immune checkpoint blockade; metastasis; microsatellite-stable; oxaliplatin
المشرفين على المادة: 04ZR38536J (Oxaliplatin)
EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
0 (Immune Checkpoint Inhibitors)
EC 2.7.11.1 (BRAF protein, human)
تواريخ الأحداث: Date Created: 20240702 Date Completed: 20240702 Latest Revision: 20240703
رمز التحديث: 20240703
مُعرف محوري في PubMed: PMC11216098
DOI: 10.1080/2162402X.2024.2372886
PMID: 38952672
قاعدة البيانات: MEDLINE
الوصف
تدمد:2162-402X
DOI:10.1080/2162402X.2024.2372886